A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer
NCT00735696
Completed
The purpose of this study is to evaluate the progression-free survival (PFS) rate at 6 months of ramucirumab administered in combination with paclitaxel and carboplatin as first-line therapy for Stage IIIB or IV non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2014
Locations: ImClone Investigational Site, Beverly Hills, California +8 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
NCT00390611
Completed
This trial will compare the efficacy and toxicity of standard first-line chemotherapy alone vs. standard chemotherapy plus sorafenib in patients with stage III/IV ovarian cancer following cytoreductive surgery. Patients with residual large volume disease and/or bowel involvement will be excluded, to minimize the risk of bowel perforation.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/12/2014
Locations: Northeast Arkansas Clinic, Jonesboro, Arkansas +16 locations
Conditions: Ovarian Cancer
Register for Updates
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
NCT00915603
Completed
This randomized, double blind, placebo controlled trial will evaluate the impact of adding everolimus to the combination of weekly paclitaxel plus bevacizumab in the first-line treatment of women with HER2-negative metastatic breast cancer. Patients will be randomized (1:1) to receive either paclitaxel/bevacizumab/everolimus (Treatment Arm 1) or paclitaxel/ bevacizumab/placebo (Treatment Arm 2). Patients will be evaluated for response to treatment every 8 weeks; responding and/or stable patients... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2014
Locations: Wilshire Oncology Medical Group, LaVerne, California +14 locations
Conditions: Metastatic Breast Cancer
Register for Updates
Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer
NCT01207102
Terminated
Taxanes (such as paclitaxel) are highly active to treat breast cancer. Abraxane® (nanoparticle albumin-bound paclitaxel) compared to standard paclitaxel improves efficacy and tolerability. When combined with a taxane, platinum agents improve response in metastatic breast cancer, with carboplatin conferring less toxicity than cisplatin. The investigators hypothesize that the combination of weekly Abraxane® and carboplatin will lengthen time to progression without producing intolerable toxicity.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/08/2014
Locations: Duke University Medical Center, Durham, North Carolina +1 locations
Conditions: Metastatic Breast Cancer
Register for Updates
A Phase II Trial of Proton Pump Inhibitors With Chemotherapy in Patients With Metastatic Head and Neck Cancer
NCT02013453
Withdrawn
The purpose of this study is to determine if the addition of proton pump inhibitors (PPIs) to standard chemotherapy can improve progression free survival in patients with head and neck cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/01/2014
Locations: University of Michigan Hospital, Ann Arbor, Michigan
Conditions: Cancer of Head and Neck
Register for Updates
Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer
NCT00003313
Completed
RATIONALE: Amifostine may be an effective treatment for the toxic side effects caused by radiation therapy and chemotherapy. It is not yet known whether chemotherapy and radiation therapy are more effective with or without amifostine for non-small cell lung cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of amifostine in treating patients who have stage II or stage III non-small cell lung cancer that cannot be surgically removed and who are undergoing chemotherapy and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2014
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +263 locations
Conditions: Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Oral Complications, Radiation Toxicity
Register for Updates
Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib
NCT00667147
Completed
This study uses the drugs Abraxane (also called ABI-007) and Vandetanib (also called Zactima and ZD6474). Abraxane has been approved by the Food and Drug Administration (FDA), for the treatment of breast cancer. Vandetanib is an experimental drug and has not been approved by the FDA for the treatment of any condition. Vandetanib has shrunk some non-small cell lung cancer, prostate cancer and thyroid cancer in some studies in humans. This combination of drugs is not approved for the treatment of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2014
Locations: University of Southern California (U.S.C.)/ Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Solid Tumors
Register for Updates
Phase II Neoadjuvant in Inflammatory Breast Cancer
NCT00756470
Terminated
The goal of this clinical research study is to learn how well lapatinib taken alone, followed by taking lapatinib with paclitaxel, and then taking lapatinib with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC75) works to help to control Inflammatory Breast Cancer (IBC). The safety of this drug combination will also be studied.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/04/2014
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers
NCT01166542
Completed
The purpose of this Phase 3 study is to evaluate overall survival and progression free survival following intravenous administration of REOLYSIN (Reovirus Serotype 3 Dearing) in combination with paclitaxel and carboplatin versus chemotherapy treatment alone, in patients with metastatic or recurrent Squamous Cell Carcinoma of the Head and Neck.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/03/2014
Locations: University of Alabama at Birmingham, Birmingham, Alabama +76 locations
Conditions: Carcinoma, Squamous Cell of the Head and Neck
Register for Updates
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma
NCT00753038
Completed
The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN® therapeutic reovirus in combination with Paclitaxel and Carboplatin is effective and safe in the treatment of squamous cell carcinoma of the head and neck.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/03/2014
Locations: Montefiore Medical Center, Bronx, New York +1 locations
Conditions: Carcinoma, Squamous Cell of the Head and Neck
Register for Updates
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
NCT00300885
Terminated
A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib in chemonaive patients with stage III-IV non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/28/2014
Locations: Not set, Birmingham, Alabama +201 locations
Conditions: Carcinoma, Non-Small Cell Lung
Register for Updates
Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
NCT00481078
Completed
This randomized phase II trial is studying carboplatin, paclitaxel, and vorinostat to see how well they work compared with carboplatin, paclitaxel, and a placebo in treating patients with stage III or stage IV non-small cell lung cancer. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2014
Locations: City of Hope, Duarte, California
Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Register for Updates